Sol-Gel Technologies Ltd. (SLGL): R&D Expense
$22.80M
Year ended 2025-12-31
+21.6%
3-year compound annual growth
-4.0%
5-year compound annual growth
+12.2%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $22.80M | +28.1% | 2026-03-19, From 2025-01-01 |
| 2024-12-31 | $17.80M | -24.4% | 2026-03-19, From 2024-01-01 |
| 2023-12-31 | $23.54M | +85.6% | 2026-03-19, From 2023-01-01 |
| 2022-12-31 | $12.68M | -37.8% | 2025-04-29, From 2022-01-01 |
| 2021-12-31 | $20.38M | -27.0% | 2024-03-13, From 2021-01-01 |
| 2020-12-31 | $27.91M | -31.2% | 2023-03-10, From 2020-01-01 |
| 2019-12-31 | $40.58M | +44.2% | 2022-04-07, From 2019-01-01 |
| 2018-12-31 | $28.15M | +9.1% | 2021-03-04, From 2018-01-01 |
| 2017-12-31 | $25.80M | +51.6% | 2020-03-24, From 2017-01-01 |
| 2016-12-31 | $17.02M | +137.0% | 2019-03-21, From 2016-01-01 |
| 2015-12-31 | $7.18M | n/a | 2018-03-26, From 2015-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $22.80M | +28.1% |
| Evofem Biosciences, Inc. (EVFM) | 2024-12-31 | $1.84M | -37.2% |
| Scynexis Inc (SCYX) | 2025-12-31 | $22.28M | -15.6% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $6.31M | -29.3% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $141.83M | -6.3% |
| uniQure N.V. (QURE) | 2025-12-31 | $140.67M | -2.2% |
| Alumis Inc. (ALMS) | 2025-12-31 | $386.00M | +45.4% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $142.27M | +13.5% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $30.81M | +14.8% |
Compare SLGL, EVFM, SCYX, CASIF side by side · Screen every company in Pharmaceutical Preparations ↗